Leukemia Debridement
Leukemia debridement generally refers to the debridement process for patients with leukemia. Leukemia is a malignant clonal disease of hematopoietic stem cells, characterized by the proliferation and accumulation of leukemia cells in the bone marrow and other hematopoietic tissues, which inhibits normal hematopoiesis.
I. Concept
1. Definition:
Leukemia is a type of malignant clonal disease of hematopoietic stem and progenitor cells. Due to differentiation disorders or stagnation at an early stage, hematopoietic cells stagnate at various stages of development, proliferate significantly in the bone marrow and other hematopoietic tissues, infiltrate other non-hematopoietic tissues and organs, and simultaneously inhibit normal hematopoiesis.
2. Clinical Manifestations:
Patients typically experience symptoms such as anemia, bleeding tendencies, and infections, accompanied by phenomena such as fever and weight loss. In severe cases, it may also lead to hepatosplenomegaly, lymphadenopathy, and other conditions.
II. Treatment
1. Chemotherapy:
Chemotherapy involves the use of chemical drugs to kill cancer cells or prevent their growth. Commonly used chemotherapy drugs include Cyclophosphamide for Injection, Vincristine Sulfate for Injection, etc.
2. Radiotherapy:
Radiation therapy utilizes high-energy rays or other forms of radiation to irradiate tumor sites, destroying the DNA of cancer cells and disabling their reproductive capabilities.
3. Targeted Therapy:
Targeted therapy is a molecular-level approach targeting specific, known oncogenic sites. Commonly used drugs include Imatinib Mesylate Tablets, Nilotinib Capsules, etc. In addition, immunotherapy can also be employed to improve outcomes.
It is recommended that patients promptly seek medical attention at reputable hospitals and actively cooperate with doctors' treatment plans to avoid delaying their condition.
